Clinical Trials

47 enrolled 21 charts 2 FDA

Myeloid

Eosinophilia, Myeloproliferative Disorders

NCT01784068 2025-09-10

ENESTfreedom

215 enrolled 7 charts 2 FDA

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT01698905 2025-09-02

ENESTop

163 enrolled 7 charts 2 FDA

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT02719574 2025-06-26

Open-label Study of FT-2102 With or Without Azacitidine or Cytarabine in Patients With AML or MDS With an IDH1 Mutation

336 enrolled 48 charts 2 FDA

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT03580655 2025-04-30

(PATHFINDER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis

LymphoidMyeloidOther hematologic neoplasm

107 enrolled 2 FDA

Leukemia, Mast-Cell, Mastocytosis, Systemic

NCT03106779 2025-04-08

Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs

233 enrolled 10 charts 2 FDA

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT01915498 2024-10-22

Phase 1/2 Study of Enasidenib (AG-221) in Adults With Advanced Hematologic Malignancies With an Isocitrate Dehydrogenase Isoform 2 (IDH2) Mutation

345 enrolled 120 charts 2 FDA

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Hematologic Neoplasms

NCT02103478 2024-08-27

Pharmacokinetic Guided Dose Escalation and Dose Confirmation With Oral Decitabine and Oral Cytidine Deaminase Inhibitor (CDAi) in Patients With Myelodysplastic Syndromes (MDS)

130 enrolled 34 charts 3 FDA

Myeloid

Myelodysplastic Syndromes

NCT03306264 2024-08-27

Study of ASTX727 vs IV Decitabine in Participants With MDS, CMML, and AML

227 enrolled 37 charts 3 FDA

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT02113982 2024-08-01

Tagraxofusp in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm or Acute Myeloid Leukemia

138 enrolled 23 charts 3 FDA

Blastic Plasmacytoid Dendritic Cell Neoplasm, Leukemia, Myeloid, Acute

NCT02081378 2024-03-18

A Phase I Study of Oral Asciminib (ABL001) in Patients With CML or Ph+ ALL

Phase 1 Completed

326 enrolled 2 FDA

LymphoidMyeloidOther hematologic neoplasm

Recurrence, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT02561988 2023-03-17

(EXPLORER) Study of BLU-285 in Patients With Advanced Systemic Mastocytosis (AdvSM) and Relapsed or Refractory Myeloid Malignancies

Phase 1 Completed

86 enrolled 2 FDA

Leukemia, Mast-Cell, Recurrence, Mastocytosis, Systemic

NCT01818492 2023-02-21

Study to Investigate Safety, Efficacy of an Anti-IFNγ mAb in Children With Primary Haemophagocytic Lymphohistiocytosis

Phase 2/3 Completed

45 enrolled 20 charts 2 FDA

Myeloid

Lymphohistiocytosis, Hemophagocytic

NCT02631070 2021-12-17

MEDALIST

229 enrolled 36 charts 3 FDA

Classical hematologyMyeloid

Anemia, Myelodysplastic Syndromes

NCT02124772 2021-07-14

Study to Investigate Safety, Pharmacokinetic (PK), Pharmacodynamic (PD) and Clinical Activity of Trametinib in Subjects With Cancer or Plexiform Neurofibromas and Trametinib in Combination With Dabrafenib in Subjects With Cancers Harboring V600 Mutations

139 enrolled 42 charts 2 FDA

CNSMyeloid

Histiocytosis, Langerhans-Cell, Neoplasms, Neuroblastoma, Neurofibroma, Plexiform

NCT02130557 2021-05-18

A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

536 enrolled 24 charts 2 FDA

Bronchiolitis Obliterans Syndrome, Bone Marrow Diseases, Hematologic Diseases, Leukemia, Leukemia, Myeloid, Neoplasms by Histologic Type, Pathologic Processes, Philadelphia Chromosome, Translocation, Genetic, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT01844765 2021-04-22

DIALOG

59 enrolled 33 charts 2 FDA